JIANGXI BIO Surges Over 17% to Record High After Subsidiary Obtains Veterinary Tetanus Antitoxin Approval

Stock News07-24 14:58

JIANGXI BIO (06915) saw its share price climb more than 17% during the trading session, reaching an intraday high of HK$12.11, a new all-time high since its listing. At the time of writing, the stock was trading at HK$12.05, up 17.1%, with a turnover of HK$39.0691 million.

In a recent company announcement, JIANGXI BIO stated that its wholly-owned subsidiary, Chifeng Boen Pharmaceutical Co., Ltd., has successfully obtained the "Veterinary Drug Product Approval Number Certificate" for a veterinary tetanus antitoxin product. This veterinary tetanus antitoxin is primarily used for the prevention and treatment of tetanus infections in animals. It provides passive immune protection for animals at risk of tetanus infection by neutralizing tetanus toxins.

The company’s board believes that securing this approval number certificate further enriches the group's product portfolio, laying a foundation for continued expansion into the animal health market. This development is expected to enhance the group's overall competitiveness and long-term growth potential.

According to its prospectus, JIANGXI BIO is China's largest provider and exporter of human tetanus antitoxin (human TAT) and a fully vertically integrated antiserum platform. Based on data from Frost & Sullivan, the company is the largest human TAT supplier in China and globally, holding market shares of 65.8% and 36.6%, respectively, by sales volume in 2024. In 2025, the company's total human TAT sales reached 29.9 million units, with 13.5 million units sold domestically in China and 16.4 million units exported to overseas markets.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1135234202?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-24 14:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1135234202","market":"us","top_or_hot":-1,"title":"JIANGXI BIO Surges Over 17% to Record High After Subsidiary Obtains Veterinary Tetanus Antitoxin Approval","media":"Stock News","content":"<p><b>JIANGXI BIO (06915)</b> saw its share price climb more than 17% during the trading session, reaching an intraday high of HK$12.11, a new all-time high since its listing. At the time of writing, the stock was trading at HK$12.05, up 17.1%, with a turnover of HK$39.0691 million.<br><br>In a recent company announcement, <b>JIANGXI BIO</b> stated that its wholly-owned subsidiary, Chifeng Boen Pharmaceutical Co., Ltd., has successfully obtained the \"Veterinary Drug Product Approval Number Certificate\" for a veterinary tetanus antitoxin product. This veterinary tetanus antitoxin is primarily used for the prevention and treatment of tetanus infections in animals. It provides passive immune protection for animals at risk of tetanus infection by neutralizing tetanus toxins.<br><br>The company’s board believes that securing this approval number certificate further enriches the group's product portfolio, laying a foundation for continued expansion into the animal health market. This development is expected to enhance the group's overall competitiveness and long-term growth potential.<br><br>According to its prospectus, <b>JIANGXI BIO</b> is China's largest provider and exporter of human tetanus antitoxin (human TAT) and a fully vertically integrated antiserum platform. Based on data from Frost & Sullivan, the company is the largest human TAT supplier in China and globally, holding market shares of 65.8% and 36.6%, respectively, by sales volume in 2024. In 2025, the company's total human TAT sales reached 29.9 million units, with 13.5 million units sold domestically in China and 16.4 million units exported to overseas markets.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>JIANGXI BIO Surges Over 17% to Record High After Subsidiary Obtains Veterinary Tetanus Antitoxin Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJIANGXI BIO Surges Over 17% to Record High After Subsidiary Obtains Veterinary Tetanus Antitoxin Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-07-24 14:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>JIANGXI BIO (06915)</b> saw its share price climb more than 17% during the trading session, reaching an intraday high of HK$12.11, a new all-time high since its listing. At the time of writing, the stock was trading at HK$12.05, up 17.1%, with a turnover of HK$39.0691 million.<br><br>In a recent company announcement, <b>JIANGXI BIO</b> stated that its wholly-owned subsidiary, Chifeng Boen Pharmaceutical Co., Ltd., has successfully obtained the \"Veterinary Drug Product Approval Number Certificate\" for a veterinary tetanus antitoxin product. This veterinary tetanus antitoxin is primarily used for the prevention and treatment of tetanus infections in animals. It provides passive immune protection for animals at risk of tetanus infection by neutralizing tetanus toxins.<br><br>The company’s board believes that securing this approval number certificate further enriches the group's product portfolio, laying a foundation for continued expansion into the animal health market. This development is expected to enhance the group's overall competitiveness and long-term growth potential.<br><br>According to its prospectus, <b>JIANGXI BIO</b> is China's largest provider and exporter of human tetanus antitoxin (human TAT) and a fully vertically integrated antiserum platform. Based on data from Frost & Sullivan, the company is the largest human TAT supplier in China and globally, holding market shares of 65.8% and 36.6%, respectively, by sales volume in 2024. In 2025, the company's total human TAT sales reached 29.9 million units, with 13.5 million units sold domestically in China and 16.4 million units exported to overseas markets.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06915","symbol_name":"江西生物","start_time":0,"source_url":"","article_id":"1135234202","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1135234202","pubTimestamp":1784876310,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"JIANGXI BIO (06915) saw its share price climb more than 17% during the trading session, reaching an intraday high of HK$12.11, a new all-time high since its listing. At the time of writing, the stock...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06915":"江西生物","BK4588":"碎股","IPOS":"Renaissance International IPO ETF","KCAI":"KraneShares China Alpha Index ETF","BK4585":"ETF&股票定投概念","VXUS":"国际股票ETF-Vanguard"},"translate_title":"子公司获得兽用破伤风抗毒素批准后，江西生物股价飙升超过17%，创历史新高","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IPOS":1,"VXUS":1,"06915":1,"KCAI":1},"content_text":"JIANGXI BIO (06915) saw its share price climb more than 17% during the trading session, reaching an intraday high of HK$12.11, a new all-time high since its listing. At the time of writing, the stock was trading at HK$12.05, up 17.1%, with a turnover of HK$39.0691 million.In a recent company announcement, JIANGXI BIO stated that its wholly-owned subsidiary, Chifeng Boen Pharmaceutical Co., Ltd., has successfully obtained the \"Veterinary Drug Product Approval Number Certificate\" for a veterinary tetanus antitoxin product. This veterinary tetanus antitoxin is primarily used for the prevention and treatment of tetanus infections in animals. It provides passive immune protection for animals at risk of tetanus infection by neutralizing tetanus toxins.The company’s board believes that securing this approval number certificate further enriches the group's product portfolio, laying a foundation for continued expansion into the animal health market. This development is expected to enhance the group's overall competitiveness and long-term growth potential.According to its prospectus, JIANGXI BIO is China's largest provider and exporter of human tetanus antitoxin (human TAT) and a fully vertically integrated antiserum platform. Based on data from Frost & Sullivan, the company is the largest human TAT supplier in China and globally, holding market shares of 65.8% and 36.6%, respectively, by sales volume in 2024. In 2025, the company's total human TAT sales reached 29.9 million units, with 13.5 million units sold domestically in China and 16.4 million units exported to overseas markets.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1135234202","isCrawlerRequest":true}